4//SEC Filing
LUNDEMOSE ANKER MD, PH.D, DSC 4
Accession 0001127602-09-025706
CIK 0000729922other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:41 PM ET
Size
9.3 KB
Accession
0001127602-09-025706
Insider Transaction Report
Form 4
LUNDEMOSE ANKER MD, PH.D, DSC
Exec. VP & Pres. OSI Prosidion
Transactions
- Award
Stock Option (Right to Buy)
2009-12-15+20,000→ 20,000 totalExercise: $35.40From: 2010-12-15Exp: 2019-12-14→ Common Stock (20,000 underlying) - Tax Payment
Common Stock
2009-12-16$32.89/sh−949$31,213→ 31,623 total - Award
Common Stock
2009-12-15+6,700→ 32,572 total
Footnotes (4)
- [F1]Represents the Restricted Stock Unit component of the annual equity compensation to executive officers. 25% of the Restricted Stock Units vest one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. The Reporting Person will receive one share of OSI Common Stock upon the vesting of each Restricted Stock Unit.
- [F2]Reflects the withholding of shares by the Company to satisfy the tax liability upon the vesting of Restricted Stock Units.
- [F3]25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years.
- [F4]Includes only options with the same termination date.
Documents
Issuer
OSI PHARMACEUTICALS INC
CIK 0000729922
Entity typeother
Related Parties
1- filerCIK 0001314821
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:41 PM ET
- Size
- 9.3 KB